V-9-M cholecystokinin nonapeptide manufacturers
|
| | V-9-M cholecystokinin nonapeptide Basic information |
| Product Name: | V-9-M cholecystokinin nonapeptide | | Synonyms: | V-9-M cholecystokinin nonapeptide;(4S)-4-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[(2S)-2-[[(1S)-1-carboxy-3-methylsulfanylpropyl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;L-Methionine, L-valyl-L-prolyl-L-valyl-L-α-glutamyl-L-alanyl-L-valyl-L-α-aspartyl-L-prolyl-;L-Valyl-L-prolyl-L-valyl-L-α-glutamyl-L-alanyl-L-valyl-L-α-aspartyl-L-prolyl-L-methionine;Cholecystokinin Precursor (24-32) (rat) H-Val-Pro-Val-Glu-Ala-Val-Asp-Pro-Met-OH;Smeglutide;Cholecystokinin Precursor;L-Methionine,L-valyl-L-prolyl-L-valyl-L-a-glutamyl-L-alanyl-L-valyl-L-a-aspartyl-L-prolyl- | | CAS: | 99291-20-0 | | MF: | C42H69N9O14S | | MW: | 956.11 | | EINECS: | 200-001-8 | | Product Categories: | Peptide;99291-20-0;API | | Mol File: | 99291-20-0.mol |  |
| | V-9-M cholecystokinin nonapeptide Chemical Properties |
| Boiling point | 1350.7±65.0 °C(Predicted) | | density | 1.306±0.06 g/cm3(Predicted) | | pka | 3.51±0.10(Predicted) | | InChIKey | AIKMAJWJXJPJNB-HNRKYVDVNA-N |
| | V-9-M cholecystokinin nonapeptide Usage And Synthesis |
| Description | V-9-M Cholecystokinin nonapeptide is a glucagon-like peptide receptor agonist, namely GLP-1 receptor agonist. Human GLP-1 is a peptide hormone secreted by intestinal L cells. Cholecystokinin Precursor (24-32), rat has apparent sedative actions and prevents experimental amnesisa in rats. | | Uses | V-9-M cholecystokinin nonapeptide belongs to the glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) class of hypoglycemic drugs, which increase insulin secretion in a glucose-dependent manner and inhibit glucagon secretion , and can promote gastric emptying, centrally suppress appetite, reduce food intake, and then reduce glucose absorption to achieve the effect of lowering blood sugar. | | Mechanism of action | V-9-M cholecystokinin nonapeptide's mechanism of action is to act on islet beta cells, promote the synthesis and secretion of insulin, stimulate the proliferation and differentiation of islet beta cells, inhibit the apoptosis of islet beta cells, increase the number of islet beta cells, and protect islet function. It can also act on islet alpha cells, inhibit the release of glucagon, and reduce the release of hepatic glucose. | | Solubility in organics | V-9-M cholecystokinin nonapeptide is soluble in DMSO solution, the reference solubility range is shown below:
 | | storage | Store at low temperatures to avoid moisture:
Powder: -20°C, 3 years.
Solvents: -80°C, 2 years. | | References | 1. Takashima A, Itoh S. Neuropharmacological properties of V-9-M, a putative neuropeptide derived from procholecystokinin, in the rat. Can J Physiol Pharmacol. 1989 Mar;67(3):223-7. DOI: 10.1016/0301-0082(90)90035-F
2. Cholecytokinin (CCK) gene-related peptides: distribution and characterization of immunoreactive pro-CCK and an amino-terminal pro-CCK fragment in rat brain. DOI: 10.1016/0006-8993(85)90813-3
3. Cao G, Beinfeld MC. Calcium-dependent pro-cholecystokinin V-9-M immunoreactive peptide release from rat brain slices and CCK-secreting rat medullary thyroid carcinoma cells in culture. Peptides. 1992 Nov-Dec;13(6):1087-90. DOI: 10.1016/0196-9781(92)90011-Q |
| | V-9-M cholecystokinin nonapeptide Preparation Products And Raw materials |
|